CAJ | 학술논문

[目的]观察培美曲赛联合铂类(顺铂、卡铂或奈达铂)一线治疗ⅢB/Ⅳ期肺腺癌患者的近期疗效及毒副反应.[方法]20例初治ⅢB/Ⅳ期肺腺癌接受培美曲塞联合铂类化疗,接受至少2个周期化疗后评价临床疗效和毒副反应.[结果]20例中完全缓解(CR )0例,部分缓解(PR)5例,病情稳定(SD)12例,病情进展(PD)3例,总有效率为(CR+PR)25％,总疾病控制率为(CR+PR+SD)85％.主要毒副反应为血液学毒性和胃肠道反应.[结论]培美曲赛联合铂类一线治疗ⅢB/Ⅳ期肺腺癌有较好的疾病控制率,毒副反应可耐受.
[목적]관찰배미곡새연합박류(순박、잡박혹내체박)일선치료ⅢB/Ⅳ기폐선암환자적근기료효급독부반응.[방법]20례초치ⅢB/Ⅳ기폐선암접수배미곡새연합박류화료,접수지소2개주기화료후평개림상료효화독부반응.[결과]20례중완전완해(CR )0례,부분완해(PR)5례,병정은정(SD)12례,병정진전(PD)3례,총유효솔위(CR+PR)25％,총질병공제솔위(CR+PR+SD)85％.주요독부반응위혈액학독성화위장도반응.[결론]배미곡새연합박류일선치료ⅢB/Ⅳ기폐선암유교호적질병공제솔,독부반응가내수.
[Objective]To observe the clinical efficacy and toxicities of pemetrexed combined with platinum as the first-line regimen for ⅢB/Ⅳ lung adenocarcinoma.[Methods]20 patients with ⅢB/Ⅳ lung adenocarcinoma received pemetrexed combined with platinum chemotherapy as the first-line treatment,the clinical efficacy and toxicities were evaluated after at least 2 cycles of chemotherapy.[Results]Among all 20 cases,no case with CR,5 cases with PR,12 cases with SD,3 cases with PD were found,the total effective rate was 25％ and the total disease control rate was 85％.The main toxicities were hone marrow depression and gastrointestinal reaction.[Conclusion]The pemetrexed combined with platinum as the first-line regimen in the treatment for ⅢB/Ⅳ lung adenocarcinoma has reliable efficacy and less toxicities.